Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Kenneth E. Lupi"'
Autor:
Meghan E. Cook, Brian R. Schuler, Michael J. Schontz, Kevin C. McLaughlin, Kenneth E. Lupi, Jeremy R. DeGrado, Chanu Rhee
Publikováno v:
Antimicrobial Stewardship & Healthcare Epidemiology, Vol 3 (2023)
Abstract Objective: To evaluate the prevalence, risk factors, and clinical impact of delays in second doses of antibiotics in patients with sepsis. Design: Single-center, retrospective, observational study. Setting: Large teaching hospital. Pa
Externí odkaz:
https://doaj.org/article/dbba18b172bf43dbb11d457c072ac70a
Autor:
Mary P. Kovacevic, PharmD, BCCCP, BCPS, Kevin M. Dube, PharmD, BCCCP, BCPS, Kenneth E. Lupi, PharmD, BCCCP, BCPS, Paul M. Szumita, PharmD, FCCM, FASHP, BCCCP, BCPS, Jeremy R. DeGrado, PharmD, BCCCP, BCPS
Publikováno v:
Critical Care Explorations, Vol 3, Iss 1, p e0330 (2021)
Objectives:. To report the prevalence of, and evaluate risk factors for, the development of hypertriglyceridemia (defined as a serum triglyceride level of > 400 mg/dL) in patients with coronavirus disease 2019 who received propofol. Design:. Single-c
Externí odkaz:
https://doaj.org/article/50ca4e5ffde441b4928a9a4903910cdf
Autor:
Lydia R Ware, Brian R Schuler, Melanie Z Goodberlet, Kaylee K Marino, Kenneth E Lupi, Jeremy R DeGrado
Publikováno v:
Journal of Intensive Care Medicine. 38:553-561
Introduction Dexmedetomidine (DEX) is commonly used with benzodiazepines for the management of alcohol withdrawal syndrome (AWS), but limited data exist regarding its use with phenobarbital (PHB). This analysis evaluated the utility of DEX in additio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc8c8943a44450ef00268a468879d205
https://doi.org/10.1177/08850666231152837
https://doi.org/10.1177/08850666231152837
Autor:
Ehsan A. Habeeb, Lena K. Tran, Melanie Z. Goodberlet, Kenneth E. Lupi, Jeremy R. DeGrado, Kevin M. Dube
Publikováno v:
Annals of Pharmacotherapy. :106002802211328
Background: Opioid-induced constipation (OIC) may occur in up to 81% of critically ill patients and can lead to many complications. Opioid antagonists are a reasonable approach and may be used for managing OIC. Objective: The purpose of this study wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8ce093e3dc4afaacb00cdd62ab0827f
https://doi.org/10.1177/10600280221132851
https://doi.org/10.1177/10600280221132851
Publikováno v:
International journal of clinical pharmacy. 44(1)
Background Intravenous (IV) insulin is commonly used for the management of hyperglycemia in critically ill patients. However, an assessment of real-world practices for the transition process from IV to Subcutaneous (SC) is lacking. Objective The obje
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e4f7d36a7ba80115e51706ae2286ef62
https://pubmed.ncbi.nlm.nih.gov/34499290
https://pubmed.ncbi.nlm.nih.gov/34499290